EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

A PROSPECTIVE STUDY ON THE EFFICACY OF TADALAFIL IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

*Abhinand S., Aadeesha A., Keerthi Krishna R. R., Reshma Raj B. L., P. S. Joy Jyothis and John Wesley I.

ABSTRACT

Background: Benign prostatic hyperplasia (BPH) is the most common problem in aged men and is responsible for the majority of urinary symptoms in males over the age of 50 years. Aim: Aim of this study is to assess the efficacy of Tadalafil 5mg OD in BPH patients. Materials and Method: The efficacy of Tadalafil was assessed in 62 patients using International prostate symptom score questionnaire and USG, then the patients was asked to review after one months of drug therapy. Results and Discussion: Tadalafil 5mg OD has significant effect on IPSS and USG before and after the treatment. Conclusion: Tadalafil 5mg OD is found to be clinically significant in improving LUTS secondary to BPH and there was significant improvement in IPSS and USG after the treatment.

Keywords: Benign prostatic hyperplasia (BPH), Lower urinary tract symptoms (LUTS), Tadalafil, International Prostate symptom Score (IPSS), Ultra sonography (USG), Erectile dysfunction (ED).

[Full Text Article] [Download Certificate]